Mode
Text Size
Log in / Sign up
N/A N=42 Randomized Other

e-Motivación: Developing and Pilot Testing an App to Improve Latinos' Screening Colonoscopy Rates

Colorectal Cancer

Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: Colonoscopy Completion — 19; 19 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Motívate (Behavioral); Video link (Behavioral)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Icahn School of Medicine at Mount Sinai
Primary completion
Apr 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Colonoscopy Completion
19; 19

Summary

Among Latinos, a fast growing and underserved population, Colorectal Cancer (CRC) is the third leading cause of cancer death in men and in women. Compared to non-Latino whites, Latinos are less likely to be diagnosed with localized CRC and more likely to be diagnosed with advanced stage disease. Of the recommended CRC screening tests, a colonoscopy allows for both the detection and removal of precancerous and cancerous polyps. Although screening colonoscopies can detect and prevent CRC, more than half of Latinos have not received a screening colonoscopy within the recommended time frame (one screening colonoscopy per ten years). The purpose of this study is to develop and begin to test an electronically-delivered motivational interviewing progressive web application (e-MI app), called Motívate. The Motívate app will be offered in both English and Spanish to patients who self-identify as Latino/a/x, after they receive a referral for a screening colonoscopy.

Eligibility Criteria

Inclusion Criteria

  • Self-identified as Latino/a/x;
  • English or Spanish-speaking;
  • Received a physician referral for a screening colonoscopy;
  • Has access to a tablet, smartphone, or computer with working Internet.

Exclusion Criteria

  • Hearing or vision impaired;
  • Aim 1 or 2 participant.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04987788). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search